Akkermansia muciniphila is a mucin-degrading bacterium commonly found in human gut. Mucins are glycoprotein components of the mucous that coats the surfaces of cells lining the respiratory, digestive, and urogenital tracts. Increased mucin production occurs in many cancers (pancreas, lung, breast, ovary, colon and other tissues). Mucins are also over-expressed in lung diseases such as asthma, bronchitis, chronic obstructive pulmonary disease (COPD) or cystic fibrosis.
Akkermansia muciniphila has been reported as a beneficial bacterium that reduces gut barrier disruption and insulin resistance.
Studies have identified a loss in abundance of Akkermansia muciniphila in patients with obesity and type 2 diabetes.
Akkermansia muciniphila has been inversely associated with:
- obesity
- diabetes
- inflammation, and
- metabolic disorders.
Due to its highly promising probiotic activities against obesity and diabetes, Akkermansia muciniphila drawn intensive interest for research and development in recent years. A number of human and animal studies have shown that the abundance of Akkermansia muciniphila in the gut can be enhanced through dietary interventions.
Akkermansia muciniphila may represent 3–5% of the microbial composition in the healthy human intestinal tract, and have a crucial role in the regulation of the gut barrier and other homeostatic and metabolic functions.
References:
– Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions, https://www.nature.com/articles/emm2017282
– Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 2004; 54: 1469–1476.
– Strategies to promote abundance of Akkermansia muciniphila, an emerging probiotics in the gut, evidence from dietary intervention studies, https://www.sciencedirect.com/science/article/pii/S1756464617301627
– Mucins in cancer: function, prognosis and therapy, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951677/
– Specific gut microbiota features and metabolic markers in postmenopausal women with obesity, http://doi.org/10.1038/nutd.2015.9
– Akkermansia muciniphila and its role in regulating host functions, https://www.sciencedirect.com/science/article/pii/S0882401015301789
Low levels associated with obesity and metabolic dysfunction.
– A low concentration of Akkermansia muciniphila in your gut could indicate a thin mucous layer, thereby resulting in a weakened gut barrier function, besides increased translocation of bacterial toxins.
– People suffering from Inflammatory Bowel Disease (IBD), obesity and Type II diabetes (T2D) tend to have lower concentrations of Akkermansia muciniphila.
– Akkermansia muciniphila concentration is also known to decrease with age.
High levels linked to multiple sclerosis.
Get a deeper understanding of your blood, urine, and stool test results.
$99 $79 per year
$6.60 per month billed annually
$15 per month
COVID-19 special offer!
$99 $79 per year
$250 single payment
At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.
Adenovirus 40/41, Akkermansia muciniphila, Ancylostoma duodenale, Anti-gliadin IgA, Ascaris lumbricoides, b-Glucuronidase, Bacillus spp., Bacteroides fragilis, Bacteroidetes, Bifidobacterium spp., Blastocystis hominis, C. difficile, Toxin A, C. difficile, Toxin B, Calprotectin, Campylobacter, Candida albicans, Candida spp., Chilomastix mesnili, Citrobacter freundii, Citrobacter spp., Clostridia (class), Cryptosporidium, Cyclospora spp., Cytomegalovirus, Dientamoeba fragilis, E. coli O157, Elastase-1, Endolimax nana, Entamoeba coli, Entamoeba histolytica, Enterobacter spp., Enterococcus faecalis, Enterococcus faecium, Enterococcus spp., Enterohemorrhagic E. coli, Enteroinvasive E. coli/Shigella, Enterotoxigenic E. coli LT/ST, Epstein Barr Virus, Escherichia spp., Faecalibacterium prausnitzii, Firmicutes, Firmicutes:Bacteroidetes Ratio, Fusobacterium spp., Geotrichum spp., Giardia, Helicobacter pylori, Klebsiella pneumoniae, Klebsiella spp., M. avium subsp. paratuberculosis, Methanobacteriaceae (family), Microsporidium spp., Morganella spp., Necator americanus, Norovirus GI/II, Occult Blood - FIT, Pentatrichomonas hominis, Proteus mirabilis, Proteus spp., Pseudomonas aeruginosa, Pseudomonas spp., Rodotorula spp., Salmonella, Secretory IgA, Shiga-like Toxin E. coli stx1, Shiga-like Toxin E. coli stx2, Staphylococcus aureus, Staphylococcus spp., Steatocrit, Streptococcus spp., Taenia spp., Trichuris trichiura, Vibrio cholerae, Virulence Factor, babA, Virulence Factor, cagA, Virulence Factor, dupA, Virulence Factor, iceA, Virulence Factor, oipA, Virulence Factor, vacA, Virulence Factor, virB, Virulence Factor, virD, Yersinia enterocolitica
